English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Chiva Pharma Acquires Global Rights to Osteoporosis Drug from Ligand

Oct. 9, 2011

Ligand Pharmaceutical announced on October 10 that it has entered into a global licensing agreement with Chinese Chiva Pharma for Fablyn (lasofoxifene), a selective estrogen receptor modulator (SERM) that was approved in the EU in 2009 for the treatment of osteoporosis in post-menopausal women at increased risk of fracture. In return for the license, Ligand will receive $4 million in licensing payments over the next eight months and is also eligible to receive milestones and royalties on worldwide sales of Fablyn.